Elan’s Tysabri multiple sclerosis (MS) drug has 31,800 patients worldwide
Jul 22nd, 2008 | By Finfacts Ireland Business & Finance Portal | Category: News worldwide
Irish drugs firm Elan and its US partner Biogen Idec today announced the two-year anniversary of Tysabri (natalizumab) as a treatment for relapsing forms of multiple sclerosis (MS), marking the reintroduction of the product in the United States (US) and the first international approval. The companies estimate that as of the end of June 2008, more than 31,800 patients worldwide are receiving Tysabri treatment.